Plavix lawyers at Pintas & Mullins Law Firm report that dozens of plaintiffs have filed suit against manufacturers Sanofi and Bristol-Myers Squibb over the blood-thinner Plavix (clopidogrel). Patients in the U.S. and abroad are claiming the drug made them develop autoimmune diseases and suffer severe hemorrhages. U.S. plaintiffs took their claims to New York state court …
Congress Strengthens FDA Oversights of Compounding Pharmacies
Compounding pharmacy lawyers at Pintas & Mullins Law Firm report on a rare feat of bipartisan agreement for a new bill that will increase federal oversight of compounding pharmacies. Leaders in the House and Senate announced the new legislation, which calls for a new tracing system to track prescription drug sales from manufacturing through distribution. The …
Debate on Fosamax Trials’ Design Defect Claims
Fosamax lawyers at Pintas & Mullins Law Firm report on the most current updates in the Fosamax federal injury trials. Plaintiffs recently filed a brief stating that a judge wrongfully used a U.S. Supreme Court ruling to preempt and deny claims of design defects against generic Fosamax manufacturers. Specifically, the judge used the SCOTUS ruling in Pliva …
Statin Drugs Linked to Cataracts
Dangerous drug lawyers at Pintas & Mullins Law Firm highlight a recent study that found that statin drugs, prescribed to lower cholesterol, may also increase the risk of developing cataracts. The large observational study found a small but significant increase in cataracts in statin users, which was further heightened the longer the patient was prescribed. The …
Problems with Compounding Pharmacies Continue to Persist
Compounding pharmacy lawyers at Pintas & Mullins Law Firm report on the most recent recall initiated by a compounding pharmacy. Leiter’s is recalling three lots of its sterile injectable products due to sterility concerns. The Leiter’s recall extends to the following products: two lots of Bevacizumab, expiration 11/03/2013, and one lot of Lidoxaine/phenylephrine, expiration 10/28/2013. Injecting …
FDA Questions Safety of Anoro Ellipta
Dangerous drug lawyers at Pintas & Mullins Law Firm report that GlaxoSmithKline’s new drug for chronic obstructive pulmonary disease (COPD), Anoro Ellipta, revealed inconsistencies in safety during FDA reviews. The federal committee will soon vote on whether to recommend its approval. The drug is a once-a-day treatment that uses 62.5 mcg of umeclidinium and 25 mcg …
Popular Antibiotic Associated with Severe Diabetic Abnormalities
Dangerous drug lawyers at Pintas & Mullins Law Firm report that a popular class of antibiotics known as fluoroquinolones are now associated with increased risk of blood sugar swings in patients with diabetes. Studies link the drugs to an increased risk of both hypo- and hyperglycemia compared to other antibiotics. In response to these and other …
Antipsychotic Drugs Raise Risk of Diabetes in Children
Dangerous drug lawyers at Pintas & Mullins Law Firm report on new research which suggests that the use of antipsychotic medications in children increases the risk of Type II diabetes, particularly in children. In response, the U.S. Department of Health and Human Services recently began a review of antipsychotic drug use in underage Medicaid beneficiaries. The …
JCB Laboratories Recalls Sterile Drug Products
Compounding pharmacy lawyers at Pintas & Mullins Law Firm announce that JCB Laboratories recently issued a recall of several lots of its sterile drug products due to microbial contamination. Among the affected medications include sodium thiosulfate, sodium citrate, and acetylcysteine. All six lots of recalled products were distributed to outpatient dialysis clinics in several states, between …
Judge Rules Fosamax Plaintiffs Not Required to Verify Injuries
Fosamax lawyers at Pintas & Mullins Law Firm confirm that a federal judge recently refused to require hundreds of Fosamax victims to substantiate their injuries. Merck, the drug’s manufacturer, previously requested that about 600 plaintiffs submit expert reports linking Fosamax to their injuries. Merck asked the judge to approve a ‘Lone Pine’ order for these cases, …
FDA Drug Security Program Targets Foreign Manufacturers
Drug recall lawyers at Pintas & Mullins Law Firm report that, in efforts to curtail contaminated or unapproved pharmaceuticals from being imported, the FDA recently implemented a new program to ensure the safety of drugs manufactured beyond U.S. borders. The new Secure Supply Chain Pilot Program is a voluntary program through which qualified applicants can expedite …
Depakote Hit with Class-Action for Off-Label Marketing and Kickbacks
Depakote lawyers at Pintas & Mullins Law Firm report that the manufacturer of popular anti-seizure drug Depakote was recently slammed with a proposed class-action lawsuit by three health benefit plans. The organizations claim the manufacturer fraudulently profited from third-parties through kickbacks for prescriptions and off-label marketing. Depakote (valproate semisodium, or divalproex sodium) was initially approved by …
Judge Rules Fosamax Generics Liable for Failure-to-Warn
Fosamax lawyers at Pintas & Mullins Law Firm report that a New York federal judge recently ruled that manufacturers of generic Fosamax can be held liable for not updating labels within a reasonable time after the brand-name did. Platiniffs claimed that the generic companies long-delayed updating their warning labels to match the brand-name version, manufactured by …
More Compounding Pharmacies Announce Recalls
Compounding pharmacy lawyers at Pintas & Mullins Law Firm confirm that Specialty Compounding, based in Cedar Park, Texas, recently announced a recall of all its sterile products. About 15 patients have already been hospitalized with blood infections after receiving injections produced at Specialty Compounding. The FDA announced on Sunday, August 11, 2013 that Specialty Compounding was …
Failure-to-Warn Generic Drug Claims to Move Forward in Court
Dangerous drug lawyers at Pintas & Mullins Law Firm report on a recent ruling by the Pennsylvania Supreme Court allowing all claims brought against makers of the generic Reglan to move forward. This is a substantial win for drug injury plaintiffs, who were devastated by the ruling of Mutual Pharmaceuticals vs Bartlett, which shielded generic manufacturers from …
Department of Health Subpoena’s Johnson & Johnson over Nucynta
Dangerous drug lawyers at Pintas & Mullins Law Firm announce that the U.S. Department of Health and Human Services recently subpoenaed Johnson & Johnson subsidiary, Janssen Pharmaceuticals, over the safety and marketing of its drug Nucynta. The Department of Health is generally responsible for investigating any possible incidents of fraud, abuse or waste of federal funds …
Wyeth’s $490M Fine for Rapamune Marketing
Dangerous drug lawyers at Pintas & Mullins Law Firm report that Wyeth Pharmaceuticals, which was recently acquired by Pfizer, recently agreed to pay the U.S. Department of Justice $490.9 million to resolve liability from the illegal marketing of Rapamune for unapproved uses. Rapamune is a kidney transplant drug approved by the FDA in 1999 only for …
FDA Releases Safety Alert for Nizoral
Dangerous drug lawyers at Pintas & Mullins Law Firm announce that the FDA recently placed strict limits on the use of Nizoral (generic ketoconazole) for any type of fungal infection. The drug may cause liver toxicity, adrenal gland problems, and dangerous interactions with other drugs. The agency approved changes to Nizoral’s labeling and added a completely …
FDA Reviews Blood Clot Drug Vorapaxar
Dangerous drug lawyers at Pintas & Mullins Law Firm report that U.S. regulators recently accepted a marketing application for a blood clot drug called vorapaxar. The experimental drug, manufactured by Merck, was sidelined in 2011 after it was shown to increase bleeding risks. The drug was acquired by Merck in 2009 when the pharmaceutical giant bought …
FDA Cancels Meeting to Review Surgery Drug Sugammadex
Dangerous drug lawyers at Pintas & Mullins Law Firm report that the FDA recently canceled an advisory-committee meeting aimed at reviewing Merck & Co.’s surgery drug, sugammadex. The agency stated it needs more time to asses results of clinical trial inspections. Advisory-committee meetings are typically called to review new types of drugs or products or when …
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »